ICON PLC ICLR
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS2.90
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.25B | $8.19B | $8.05B | $7.74B | $5.48B | $2.80B | $2.81B | $2.60B | $1.76B | $1.67B |
| Cost of revenue | — | $5.85B | $5.72B | $5.53B | $3.97B | $1.98B | $1.97B | $1.82B | $1.03B | $961.3M |
| Gross profit | — | $2.34B | $2.33B | $2.21B | $1.51B | $817.4M | $831.7M | $777.6M | $731.1M | $705.2M |
| SG&A | $780.1M | $728.3M | $768.6M | $778.8M | $585.3M | $342.4M | $332.7M | $325.8M | $323.7M | $325.7M |
| Total operating expenses | $7.81B | $7.16B | $7.15B | $6.95B | $5.10B | $2.41B | $2.37B | $2.22B | $1.42B | $1.35B |
| Operating income | $442.8M | $1.03B | $904.7M | $795.2M | $378.5M | $391.5M | $433.4M | $373.4M | $338.3M | $311.7M |
| Interest expense | $197.5M | $237.2M | $336.7M | $229.7M | $182.4M | $13.0M | $13.3M | — | — | — |
| Pre-tax income | $252.5M | $803.8M | $573.0M | $567.9M | $196.7M | $381.2M | $427.0M | $364.6M | $328.1M | $300.2M |
| Income tax | $23.1M | $64.6M | $18.4M | $59.4M | $41.3M | $47.9M | $51.1M | $42.0M | $46.6M | $38.0M |
| Net income | $229.3M | $739.1M | $554.2M | $505.3M | $153.2M | $332.3M | $374.0M | $322.7M | $281.5M | $262.2M |
| EPS, basic | 2.92 | 8.96 | 6.75 | 6.20 | 2.28 | 6.20 | 6.85 | 5.96 | 5.20 | 4.75 |
| EPS, diluted | 2.90 | 8.90 | 6.70 | 6.13 | 2.25 | 6.15 | 6.79 | 5.89 | 5.13 | 4.65 |
| Shares, diluted (wtd. avg.) | $79.0M | $83.0M | $82.7M | $82.5M | $68.1M | $53.3M | $54.3M | $54.8M | $54.8M | $56.4M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $647.3M | $538.8M | $378.1M | $288.8M | $752.2M | $840.3M | $520.3M | $395.9M | $282.9M | $192.5M |
| Short-term investments | $0 | $0 | $2.0M | $1.7M | $1.7M | $1.7M | $49.6M | $59.9M | $77.6M | $68.0M |
| Receivables | $1.47B | $1.39B | $1.76B | $1.73B | $1.34B | $715.3M | $527.7M | $414.8M | $379.5M | $416.2M |
| Inventory | — | — | — | — | $5.8M | $4.8M | $3.2M | $2.3M | $2.2M | $2.4M |
| Total current assets | $3.50B | $3.28B | $3.29B | $3.23B | $2.94B | $2.10B | $1.62B | $1.33B | $1.10B | $958.0M |
| Property, plant and equipment | $395.7M | $382.9M | $361.2M | $350.3M | $336.4M | $174.3M | $165.1M | $158.7M | $163.1M | $149.0M |
| Goodwill | $8.73B | $9.05B | $9.02B | $8.97B | $9.04B | $936.3M | $883.2M | $756.3M | $769.1M | $616.1M |
| Other intangibles | $3.25B | $3.56B | $3.86B | $4.28B | $4.71B | $66.5M | $67.9M | $54.1M | $71.6M | $56.6M |
| Total assets | $16.27B | $16.63B | $16.86B | $17.19B | $17.39B | $3.44B | $2.91B | $2.35B | $2.15B | $1.83B |
| Accounts payable | $192.1M | $173.0M | $131.6M | $81.2M | $90.8M | $51.1M | $24.1M | $13.3M | $18.6M | $8.7M |
| Total current liabilities | $3.20B | $2.64B | $2.73B | $2.69B | $2.48B | $1.12B | $1.13B | $610.6M | $566.1M | $494.4M |
| Long-term debt | $2.87B | $3.40B | $3.67B | $4.60B | $5.38B | $348.5M | — | — | — | — |
| Total liabilities | $7.08B | $7.19B | $7.65B | $8.69B | $9.32B | $1.59B | $1.25B | $1,000.0M | $955.6M | $880.7M |
| Retained earnings | $2.12B | $2.64B | $2.40B | $1.82B | $1.42B | $1.26B | $1.11B | $888.3M | $742.8M | $587.8M |
| Total equity | $9.19B | $9.44B | $9.21B | $8.53B | $8.07B | $1.85B | $1.62B | $1.35B | $1.19B | $945.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.04B | $1.29B | $1.16B | $563.3M | $829.1M | $568.0M | $412.5M | $268.6M | $383.1M | $259.2M |
| Depreciation and amortisation | $383.0M | $488.5M | $586.0M | $569.5M | $315.0M | $66.1M | $61.5M | $50.6M | $43.4M | $42.1M |
| Stock-based compensation | $102.0M | $45.9M | $55.7M | $70.5M | $133.8M | $26.3M | $26.8M | $31.6M | $30.6M | $40.3M |
| Capital expenditure | $174.2M | $168.1M | $140.7M | $142.2M | $93.8M | $40.9M | $38.9M | $48.4M | $44.7M | $42.6M |
| Investing cash flow | -$187.5M | -$266.8M | -$226.7M | -$145.9M | -$6.02B | -$46.6M | -$162.0M | -$37.3M | -$177.8M | -$74.8M |
| Financing cash flow | -$771.3M | -$837.2M | -$844.0M | -$864.2M | $5.11B | -$208.3M | -$125.4M | -$113.0M | -$119.3M | -$93.7M |
| Buybacks | $750.0M | $500.0M | $0 | $100.0M | $0 | $175.0M | $146.9M | $129.0M | $133.1M | $110.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-038487.
Others in SIC 8731
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $44.69B | 34.2x | 5.9% |
| INCY | INCYTE CORP | $25.32B | 19.8x | 21.2% |
| MEDP | Medpace Holdings, Inc. | $16.50B | 38.7x | 20.0% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $13.77B | — | -0.9% |
| ABSI | Absci Corp | $1.51B | — | -38.2% |
| OABI | OmniAb, Inc. | $629.5M | — | -29.3% |
| NRC | NRC HEALTH | $476.2M | 0.4x | -4.0% |
| MXCT | MAXCYTE, INC. | $132.1M | — | -5.7% |